SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Daniel Acker — Bloomberg via Getty Images

57

Pfizer

PFE

Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company is now mulling whether to sell its consumer healthcare business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.

Looking for leads, investment insights, or competitive intelligence?

CEO

Ian C. Read

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York City

Years on Fortune 500 List

24

Employees

90,200

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$52,546-0.5%
Profits ($M)$21,308.0195.3%
Assets ($M)$171,797
Total Stockholder Equity ($M)$71,308
Market Value — as of March 29, 2018 ($M)$211,115
Profit Ratios
Profit as % of Revenues40.6%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity29.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.52
EPS % Change (from 2016)200.9%
EPS % Change (5 year annual rate)12.7%
EPS % Change (10 year annual rate)11.6%
Total Return
Total Return to Investors (2017)15.7%
Total Return to Investors (5 year, annualized)11.4%
Total Return to Investors (10 year, annualized)9.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

More Than 200 Critical Drugs May Not Be There When You Need Them

The inside story of how one company—Pfizer—and one bad acquisition has led to a dangerous hospital crisis.

Read More →
Why Pfizer and Merck Stock Both Slumped After Their Earnings Reports

Pfizer stock was down more than 4%, while Merck fell 2% despite beating profit expectations.

Read More →
Pfizer Shares Deflate After Another Quarter Without a Big Transaction

Revenue overall rose just 1% to $12.9 billion last quarter, lower than the $13.1 billion projected by analysts.

Read More →